文献速递帕金森病与运动障碍

尼洛替尼治疗帕金森病的2期随机临床试验:安全性与生物标志物影响

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项单中心2期随机双盲安慰剂对照试验纳入75例中重度帕金森病患者,按1:1:1随机接受安慰剂、尼洛替尼150mg或300mg治疗12个月。尼洛替尼总体安全性可接受,但严重不良事件在150mg组(24%)和300mg组(48%)高于安慰剂组(16%)。脑脊液探索性生物标志物出现改变,支持开展3期研究。

要点

  • 尼洛替尼150mg和300mg总体安全性可接受,但严重不良事件高于安慰剂组。
  • 150mg组脑脊液多巴胺代谢产物高香草酸和DOPAC升高。
  • 150mg组α-突触核蛋白寡聚体降低,两剂量组磷酸化tau均降低。

核心结论

  • 尼洛替尼在该研究中显得相当安全,并可在脑脊液中检测到。
  • 探索性生物标志物随尼洛替尼治疗出现改变。
  • 这些数据将指导开展3期研究以探讨尼洛替尼对帕金森病患者的疗效。

研究设计与样本

  • 单中心、2期、随机、双盲、安慰剂对照试验,共75例患者按1:1:1随机分组。
  • 患者为经英国脑库诊断标准确诊的帕金森病,症状已用左旋多巴和/或多巴胺受体激动剂等药物稳定。
  • 干预为口服尼洛替尼或安慰剂每日一次,持续12个月,随后3个月洗脱期。
  • 招募自2017年5月17日至2018年4月28日,随访于2019年8月10日结束。

主要发现

  • 75例患者中55例为男性(73.3%),平均(SD)年龄68.4(8.2)岁。
  • 严重不良事件在尼洛替尼150mg组为6例(24%)、300mg组为12例(48%),安慰剂组为4例(16%)。
  • 150mg组脑脊液高香草酸升高159.80nM(90% CI 7.04-312.60nM,P=.04),DOPAC升高4.87nM(90% CI 1.51-8.23nM,P=.01)。
  • 300mg组DOPAC升高7.52nM(90% CI 2.35-12.69nM,P=.01)。
  • 150mg组α-突触核蛋白寡聚体降低-0.04pg/mL(90% CI -0.08至0.01pg/mL,P=.03),300mg组未见此变化。

临床怎么用

  • 该2期试验结果为尼洛替尼在帕金森病中的后续3期研究设计提供依据。
  • 当前数据尚不足以支持尼洛替尼用于帕金森病的常规临床治疗。

局限性

  • 研究为单中心设计,样本量较小(共75例)。
  • 生物标志物分析为探索性终点。
  • 严重不良事件在尼洛替尼组高于安慰剂组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: This study evaluated nilotinib safety and its effects on biomarkers as a potential disease-modifying drug in Parkinson disease. OBJECTIVES: To assess nilotinib effects on safety and pharmacokinetics and measure the change in exploratory biomarkers in patients with moderately severe Parkinson disease. DESIGN, SETTING, AND PARTICIPANTS: This was a single-center, phase 2, randomized, double-blind, placebo-controlled trial with 300 patients approached in clinic; of these, 200 declined to participate, 100 were screened, 25 were excluded, and 75 were randomized 1:1:1 into placebo; nilotinib, 150-mg; or nilotinib, 300-mg groups. Recruitment started on May 17, 2017, and ended April 28, 2018, and follow-up ended August 10, 2019. Parkinson disease was confirmed according to the UK Brain Bank diagnostic criteria and symptoms were stabilized with use of optimal levodopa and/or dopamine agonists and other medications used in Parkinson disease. INTERVENTIONS: Nilotinib vs placebo, administered orally once daily for 12 months followed by a 3-month washout period. MAIN OUTCOMES AND MEASURES: It was hypothesized that nilotinib is safe and can be detected in the cerebrospinal fluid, where it alters exploratory biomarkers via inhibition of Abelson tyrosine kinase and potentially improves clinical outcomes. RESULTS: Of the 75 patients included in the study, 55 were men (73.3%); mean (SD) age was 68.4 (8.2) years. Doses of 150 or 300 mg of nilotinib were reasonably safe, although more serious adverse events were detected in the nilotinib (150 mg: 6 [24%]; 300 mg: 12 [48%]) vs placebo (4 [16%]) groups. The 150-mg nilotinib group showed an increase in cerebrospinal fluid levels of the dopamine metabolites homovanillic acid (159.80nM; 90% CI, 7.04-312.60nM; P = .04) and 3,4-dihydroxyphenylacetic acid (4.87nM; 90% CI, 1.51-8.23nM; P = .01), and the 300-mg nilotinib group showed an increase in 3,4-dihydroxyphenylacetic acid (7.52nM; 90% CI, 2.35-12.69nM; P = .01). The nilotinib 150-mg but not the nilotinib 300-mg group demonstrated a reduction of α-synuclein oligomers (-0.04 pg/mL; 90% CI, -0.08 to 0.01 pg/mL; P = .03). A significant reduction of hyperphosphorylated tau levels was seen in the nilotinib 150-mg (-10.04 pg/mL; 90% CI, -17.41 to -2.67 pg/mL; P = .01) and nilotinib 300-mg (-12.05 pg/mL; 90% CI, -19.21 to -4.90 pg/mL; P = .01) groups. CONCLUSIONS AND RELEVANCE: In this study, nilotinib appeared to be reasonably safe and detectable in the cerebrospinal fluid. Exploratory biomarkers were altered in response to nilotinib. Taken together, these data will guide the development of a phase 3 study to investigate the effects of nilotinib therapy in patients with Parkinson disease. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02954978.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Pagan FL, Hebron ML, Wilmarth B, et al. Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 31841599. doi:10.1001/jamaneurol.2019.4200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。